The Safety and Efficacy of Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or GemOx in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma: A Prospective, Multicenter, Open-label, Phase Ib/II Clinical Study

This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of golidocitinib combined with mitoxantrone hydrochloride liposome or GemOx in the treatment of relapsed or refractory peripheral T-cell lymphoma

开始日期2025-08-01

申办/合作机构

中山大学

NCT07070479

/ Recruiting临床2期IIT

A Bayesian Adaptive Phase II Randomized Trial Comparing Ivonescimab, Ivonescimab Plus Nimotuzumab, Liposomal Mitoxantrone Plus Anti-PD-1 Antibody, and Liposomal Irinotecan Plus S-1 in Patients With PD-1-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

This is a prospective, Bayesian adaptive, phase II clinical trial designed to evaluate the safety and efficacy of four treatment regimens in patients with recurrent (unamenable to local therapy) or metastatic nasopharyngeal carcinoma (NPC) who have failed after at least one prior platinum-containing standard regimen and anti-PD-1/PD-L1 therapy.
The four treatment arms include:
1. Ivonescimab monotherapy,
2. Ivonescimab combined with nimotuzumab,
3. Liposomal mitoxantrone plus anti-PD-1 antibody, and
4. Liposomal irinotecan plus S-1.

开始日期2025-06-24

申办/合作机构

中山大学

NCT07028086

/ Recruiting临床2期IIT

Prospective, Multicenter, Single-Arm Clinical Study of Mitoxantrone Liposome Combined With Azacitidine and Venetoclax in the Treatment of Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma

The mitoxantrone liposomal enhances the tissue permeability of mitoxantrone by incorporating liposomal groups compared to the conventional mitoxantrone formulation, while also reducing the concentration of free mitoxantrone, thereby minimizing drug side effects-particularly cardiotoxicity.
Building upon this, the investigators aim to investigate the efficacy and safety of the liposomal mitoxantrone hydrochloride injection in patients with secondary AML, AML with extramedullary involvement, or myeloid sarcoma, in order to explore alternative therapeutic strategies for these populations.

开始日期2025-06-20

申办/合作机构

上海交通大学医学院附属瑞金医院

100 项与盐酸米托蒽醌脂质体相关的临床结果

登录后查看更多信息

100 项与盐酸米托蒽醌脂质体相关的转化医学

登录后查看更多信息

100 项与盐酸米托蒽醌脂质体相关的专利（医药）

登录后查看更多信息

5,206

项与盐酸米托蒽醌脂质体相关的文献（医药）

2025-10-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A target-response ratiometric or turn-off fluorescent dual-mode platform for simultaneous detection of multiple anticancer drugs

Article

作者: Yu, Zhendi ; Feng, Da-Qian ; Fang, Bo ; Liu, Guoliang ; Li, Hengye ; Zhang, Wenfeng

The anthracycline including doxorubicin (DOX), daunorubicin (DAU) and mitoxantrone (MTX) plays crucial roles in human health due to their notably clinical efficacy in various malignant tumors. There is few molecular probe and abiotic sensor that can simultaneously discriminate among anthracycline drugs. Herein, a target-response ratiometric and turn-off fluorescent dual-mode platform was designed for simultaneous detection of multiple anticancer drugs based on blue-emitting carbon dots (BCDs). In the presence of anthracycline, specific absorption and formation of the BCDs-anthracycline conjugate was achieved via electrostatic interaction and hydrophobic force, leading to ratiometric signal or quenched fluorescent response, thereby achieving ratiometric or turn-off dual-mode detection. Specifically, the introduction of both DOX and DAU produce ratiometric response of BCDs due to fluorescence resonance energy transfer (FRET) and dynamic quenching while MTX only induce reduced fluorescent response attribute to photoinduced electron transfer (PET) and dynamic quenching. The linear range calculated is 1-98, 1-91 and 1-77 μM for DOX, DAU and MTX, respectively, with a limit of detection of 0.02, 0.05 and 0.06 μM. Taking advantage of target-response self-verification ratiometric and sensitive fluorescent detection, the dual-mode platform was proposed and applied for successful discrimination of anthracycline drugs. This study opens a new path for multiplex drugs analysis in a facile and rapid way.

2025-10-01·ARTIFICIAL INTELLIGENCE IN MEDICINE

DDintensity: Addressing imbalanced drug-drug interaction risk levels using pre-trained deep learning model embeddings

Article

作者: Wang, Yuchen ; Zheng, Zetian ; Huang, Lei ; Peng, Chengbin ; Chen, Xingjian ; Xie, Weidun ; Wong, Ka-Chun ; Gullerova, Monika ; Liu, Zhichao ; Zhang, Ruoxuan ; Zhang, Xiao

Imbalanced datasets have been a persistent challenge in bioinformatics, particularly in the context of drug-drug interaction (DDI) risk level datasets. Such imbalance can lead to biased models that perform poorly on underrepresented classes. To address this issue, one strategy is to construct a balanced dataset, while another involves employing more advanced features and models. In this study, we introduce a novel approach called DDintensity, which leverages pre-trained deep learning models as embedding generators combined with LSTM-attention models to address the imbalance in DDI risk level datasets. We tested embeddings from various domains, including images, graphs, and textual corpus. Among these, embeddings generated by BioGPT achieved the highest performance, with an Area Under the Curve (AUC) of 0.97 and an Area Under the Precision-Recall curve (AUPR) of 0.92. Our model was trained on the DDinter and further validated using the MecDDI dataset. Additionally, case studies on chemotherapeutic drugs, DB00398 (Sorafenib) and DB01204 (Mitoxantrone) used in oncology, were conducted to demonstrate the specificity and effectiveness of the this methods. Our approach demonstrates high scalability across DDI modalities, as well as the discovery of novel interactions. In summary, we introduce DDIntensity as a solution for imbalanced datasets in bioinformatics with pre-trained deep-learning embeddings.

2025-08-01·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Simulated sunlight-enhanced peroxymonosulfate activation via S-scheme BiOBr/g-C3N4 aerogel heterojunction for multi-pollutant remediation: Band structure and interface engineering

Article

作者: Dong, Gaolei ; Gao, Min ; Zhang, Yangdong ; Wu, Xiao ; Lin, Mei ; Jiang, Xingan ; Zhao, Chunlin ; Wu, Yourong ; Lin, Cong ; Huang, Xi

The intricate composition of real-world aquatic systems significantly constrains the improved overall performance of powder catalysts, meanwhile their recyclability is inferior to the bulk counterparts (e.g. aerogels). Herein, by loading BiOBr onto g-C₃N₄ nanosheets and combining them with agarose, an S-scheme heterojunction aerogel (abbreviated as BCA) was synthesized, whose structure was confirmed by the density functional theory calculation. Importantly, the BCA could activate peroxymonosulfate (PMS) under simulated sunlight for degrading multi-pollutant. And the BCA/PMS/Light system efficiently degraded various organic contaminants in aqueous environments, achieving a high degradation rate constant of 0.1503 min^-1 for rhodamine B (RhB), significantly surpassing the performance of CA/PMS/Light (0.0378 min^-1) and BCA/PMS (0.0763 min^-1) systems. Free radical quenching experiment and electron paramagnetic resonance analysis reveal that ¹O₂, •O₂^-, •OH and SO₄•^- in the BCA/PMS/Light system were pivotal in RhB degradation, with a dominant non-radical mechanism. Additionally, Fukui function analysis pinpointed the primary reaction sites within the RhB molecule. The photocatalytic heterojunction aerogel exhibits outstanding stability, environmental sustainability and versatility, which can guide the development of simulated sunlight-driven PMS activation for multi-pollutant degradation, catering for scalable water treatment applications.

项与盐酸米托蒽醌脂质体相关的新闻（医药）

2025-08-04

·ioncology

ESMO 2025丨血液肿瘤相关专场重磅研究抢先看

点击蓝字关注我们编者按：2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17日至21日在德国柏林盛大举办。届时，来自世界各地的临床医生、研究人员、患者倡导者、记者和医疗行业专业人士将共聚一堂，展示开创性的发现、前沿治疗方法，并倡导协作方式，推动肿瘤治疗的未来发展。近日，大会官网公布了除LBA外的入选摘要标题。《肿瘤瞭望-血液时讯》特整理血液肿瘤相关专场（Proffered Paper session & Mini Oral session）的重磅研究，邀您提前锁定前沿进展。特邀论文报告 Proffered Paper session 日期：2025年10月17日（星期五）地点：Bochum Auditorium - Hall 6.1 时间：14:00 - 15:30（当地时间） One LBA TBC 讲者：待定摘要号：1240O 英文题目：CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory Large B-cell Lymphoma: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial 中文题目：CD19/CD22双特异性CAR-T细胞治疗复发/难治性大B细胞淋巴瘤：一项前瞻性、单臂、单中心、II期临床试验汇报者：王亮（首都医科大学附属北京同仁医院）摘要号：1241O 英文题目：Anti-PD-1-Antibody (Tislelizumab) Combined with Chidamide, Lenalidomide and Etoposide for the treatment of refractory/relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial 中文题目：抗PD-1抗体（替雷利珠单抗）联合西达本胺、来那度胺和依托泊苷治疗难治性/复发性鼻型结外自然杀伤/T细胞淋巴瘤：一项前瞻性、多中心、单臂、II期试验的初步结果汇报者：张蕾（郑州大学第一附属医院）小型口头报告 Mini Oral session 日期：2025年10月19日（星期日）地点：Solingen Auditorium - Hall 23 时间：08:30 - 10:00（当地时间）摘要号：1242MO 英文题目：Sustained marrow and imaging MRD negativity can lead to lenalidomide discontinuation following ASCT in multiple myeloma: Updated results from a prospective cohort study 中文题目：持续的骨髓及影像学MRD阴性可支持多发性骨髓瘤患者在ASCT后停用来那度胺：一项前瞻性队列研究的最新结果汇报者：Panagiotis Malandrakis (希腊雅典) 摘要号：1243MO 英文题目：Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim 18F-FDG PET-CT Analysis and the NCCN-IPI: A Multicentre Retrospective Study 中文题目：整合中期18F-FDG PET-CT分析和NCCN-IPI对弥漫性大B细胞淋巴瘤进行风险分层：一项多中心回顾性研究汇报者：王杰松（福建省肿瘤医院）摘要号：1244MO 英文题目： Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma 中文题目：新诊断多发性骨髓瘤患者基于序贯全身磁共振成像的疗效评估汇报者：Ioannis Ntanasis-Stathopoulos (希腊雅典) 摘要号：1245MO 英文题目：Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: Updated Results of the Phase II Study 中文题目：盐酸米托蒽醌脂质体联合西达本胺治疗复发或难治性外周T细胞淋巴瘤：II期研究更新结果汇报者：李志铭（中山大学肿瘤防治中心）摘要号：1246MO 英文题目：Single-Cell Atlas of Circulating Immunity identifies shared specific DLBCL signatures for predicting Response to R-CHOP and Anti-CD19 CAR T Therapies 中文题目：单细胞循环免疫图谱揭示了可预测对R-CHOP和抗CD19 CAR-T疗法应答的共同特异性DLBCL特征汇报者：张思聪（天津医科大学肿瘤医院）摘要号：1247MO 英文题目：Molecular Landscape of Distinct Follicular Lymphoma Histologic Grades: Insights from Genomic and Transcriptome Analyses 中文题目：不同滤泡性淋巴瘤组织学分级的分子图谱：来自基因组和转录组分析的见解汇报者：孙聪（天津医科大学肿瘤医院）摘要号：1248MO 英文题目：Changes in Peripheral Blood Leukemia Stem Cells, Immune Cell Subsets, Cytokines, and Cellular Differentiation Status Before and After Venetoclax-Containing Regimen Treatment for Acute Myeloid Leukemia 中文题目：急性髓系白血病含维奈克拉方案治疗前后外周血白血病干细胞、免疫细胞亚群、细胞因子及细胞分化状态的变化汇报者：Xinyu Sun（中国合肥）摘要号：1249MO 英文题目：Macrophage reprogrammer Bexmarilimab Plus Azacitidine in Myelodysplastic Syndrome: PK/PD and biomarker results from the Phase 1/2 BEXMAB Study 中文题目：巨噬细胞重编程Bexmarilimab联合阿扎胞苷治疗骨髓增生异常综合征：1/2期BEXMAB研究的PK/PD和生物标志物结果汇报者：Amer M. Zeidan (美国纽黑文) 摘要号：1250MO 英文题目：Outcomes of Patients with Chronic Myeloid Leukemia Receiving Second-Line Therapy 中文题目：慢性粒细胞白血病患者接受二线治疗的疗效汇报者：Fadi G. Haddad (美国休斯顿) （来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

细胞疗法临床2期免疫疗法临床1期临床结果

2025-07-27

·ioncology

2025年ESMO大会摘要标题公布：中国血液肿瘤领域28项创新研究闪耀入选

点击蓝字关注我们编者按：作为全球肿瘤学领域的顶级盛会，2025年欧洲肿瘤内科学会年会（ESMO 2025）将于10月17日至21日在德国柏林盛大举办。届时，来自世界各地的临床医生、研究人员、患者倡导者、记者和医疗行业专业人士将齐聚一堂，展示开创性的发现、前沿治疗方法，并倡导协作方式，推动肿瘤治疗的未来发展。日前，大会公布了本次入选摘要的标题，其中在血液肿瘤领域共有28项中国研究入选（如遗漏欢迎留言补充），展示了中国在该领域的最新突破与创新成果。以下是入选摘要及相关汇报者的信息，敬请关注。特邀论文报告Proffered Paper session摘要号：1240O英文题目：CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory Large B-cell Lymphoma: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial中文题目：CD19/CD22双特异性CAR-T细胞治疗复发/难治性大B细胞淋巴瘤：一项前瞻性、单臂、单中心、II期临床试验汇报者：王亮（首都医科大学附属北京同仁医院）摘要号：1241O英文题目：Anti-PD-1-Antibody (Tislelizumab) Combined with Chidamide, Lenalidomide and Etoposide for the treatment of refractory/relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial中文题目：抗PD-1抗体（替雷利珠单抗）联合西达本胺、来那度胺和依托泊苷治疗难治性/复发性鼻型结外自然杀伤/T细胞淋巴瘤：一项前瞻性、多中心、单臂、II期试验的初步结果汇报者：张蕾（郑州大学第一附属医院）小型口头报告Mini Oral session摘要号：1243MO英文题目：Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim 18F-FDG PET-CT Analysis and the NCCN-IPI: A Multicentre Retrospective Study中文题目：整合中期18F-FDG PET-CT分析和NCCN-IPI对弥漫性大B细胞淋巴瘤进行风险分层：一项多中心回顾性研究汇报者：王杰松（福建省肿瘤医院）摘要号：1245MO英文题目：Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: Updated Results of the Phase II Study中文题目：盐酸米托蒽醌脂质体联合西达本胺治疗复发或难治性外周T细胞淋巴瘤：II期研究更新结果汇报者：李志铭（中山大学肿瘤防治中心）摘要号：1246MO英文题目：Single-Cell Atlas of Circulating Immunity identifies shared specific DLBCL signatures for predicting Response to R-CHOP and Anti-CD19 CAR T Therapies中文题目：单细胞循环免疫图谱揭示了可预测对R-CHOP和抗CD19 CAR-T疗法应答的共同特异性DLBCL特征汇报者：张思聪（天津医科大学肿瘤医院）摘要号：1247MO英文题目：Molecular Landscape of Distinct Follicular Lymphoma Histologic Grades: Insights from Genomic and Transcriptome Analyses中文题目：不同滤泡性淋巴瘤组织学分级的分子图谱：来自基因组和转录组分析的见解汇报者：孙聪（天津医科大学肿瘤医院）摘要号：1248MO英文题目：Changes in Peripheral Blood Leukemia Stem Cells, Immune Cell Subsets, Cytokines, and Cellular Differentiation Status Before and After Venetoclax-Containing Regimen Treatment for Acute Myeloid Leukemia中文题目：急性髓系白血病含维奈克拉方案治疗前后外周血白血病干细胞、免疫细胞亚群、细胞因子及细胞分化状态的变化汇报者：Xinyu Sun（中国合肥）壁报与电子壁报Posters and ePosters摘要号：1251P 英文题目：DLBCL-associated PIM1 mutation drives ANXA2 relocation on the membrane and promotes lymphomagenesis through PI3K/AKT/mTOR pathway中文题目：DLBCL相关的PIM1突变驱动ANXA2移位至膜上并通过PI3K/AKT/mTOR通路促进淋巴瘤发生汇报者：Yaxiao Lu (中国天津)摘要号：1254P英文题目：Clinical features, management, and prognostic factors of patients with primary pulmonary mucosa-associated lymphoid tissue lymphoma中文题目：原发性肺黏膜相关淋巴组织淋巴瘤患者的临床特征、管理及预后因素汇报者：Yizhen Liu (中国上海)摘要号：1256P英文题目：Integrating Transcriptomic Profiling and Machine Learning: A Clinically Actionable Prognostic Model for Infant Acute Myeloid Leukemia中文题目：整合转录组学分析与机器学习：婴儿急性髓性白血病的临床可操作预后模型汇报者：Yu Tao (中国重庆)摘要号：1257P英文题目：Phase I Randomized, Double-Blind, Parallel Study to Compare Pharmacokinetics, Safety, and Immunogenicity of QL2109 with DARZALEX FASPRO? in Healthy Male Participants中文题目：比较QL2109与DARZALEX FASPRO在健康男性参与者中的药代动力学、安全性和免疫原性的I期随机、双盲、平行研究汇报者：Xingjiang Hu (中国杭州)摘要号：1262P英文题目：A Deep Learning-Based Digital Pathology Model for Predicting MYC, BCL2, and BCL6 Rearrangements in DLBCL中文题目：基于深度学习的数字病理模型用于预测DLBCL中MYC、BCL2和BCL6的重排汇报者：Xujie Sun (中国北京)摘要号：1264P英文题目：Orelabrutinib plus Rituximab-based chemoimmunotherapy regimens in relapsed or refractory marginal zone lymphoma: a multicentric phase II trial中文题目：奥布替尼联合利妥昔单抗治疗复发或难治性边缘区淋巴瘤的化学免疫治疗方案：一项多中心II期临床试验汇报者：Shaohua Wu (中国太原)摘要号：1265P英文题目：Orelabrutinib with Anti-CD20 monoclonal antibodies is highly effective and well tolerated as first-line therapy for marginal zone B cell lymphoma中文题目：奥布替尼联合抗CD20单克隆抗体一线治疗边缘区B细胞淋巴瘤的疗效显著且耐受性良好汇报者：Na Yao (中国北京)摘要号：1266P英文题目：Proteolysis-targeting chimera (PROTAC) targeting BTK degradation for cancer therapy in mantle cell lymphoma中文题目：靶向BTK降解的蛋白降解靶向嵌合体（PROTAC）在套细胞淋巴瘤癌症治疗中的应用汇报者：Xiaohui Wang (中国天津)摘要号：1269P英文题目：Loss of MGAT3 promotes airway fibrosis in patients with bronchiolitis obliterans by enhancing TGF-β signaling中文题目：MGAT3缺失通过增强TGF-β信号通路促进支气管炎性小气道纤维化汇报者：Wei Ge (中国苏州)摘要号：1270P英文题目：Safety and efficacy of a pre-phase with dexamethasone followed by fractioned R-CHOP in diffuse large B cell lymphoma patients with gastrointestinal involvement at diagnosis中文题目：地塞米松预处理联合R-CHOP分次治疗对确诊时有胃肠道损害的弥漫大B细胞淋巴瘤患者的安全性和有效性汇报者：Ke Cui (中国上海)摘要号：1274P英文题目：A transcriptomic model accurately predicting hematopoietic stem cell transplantation survival in pediatric acute myeloid leukemia中文题目：准确预测儿童急性髓系白血病造血干细胞移植存活率的转录组模型汇报者：Yance Feng (中国重庆)摘要号：1275P英文题目：Efficacy and Safety of Low-Dose TBI Combined MAC Regimen for HSCT in High-Risk AML Patients with Active Disease中文题目：低剂量TBI联合MAC方案对活动期高危AML患者造血干细胞移植的疗效及安全性汇报者：Pengfei Shi (中国杭州)摘要号：1276P 英文题目：Efficacy and Safety of Tafasitamab Combined with Lenalidomide in Patients with Diffuse Large B-Cell Lymphoma: A Matched-Adjusted Indirect Comparison Based on a Global Trial中文题目：Tafasitamab联合来那度胺治疗弥漫大B细胞淋巴瘤的疗效和安全性：基于全球试验的匹配调整间接比较汇报者：Wenyu Li (中国广州)摘要号：1279P英文题目：Risk Stratification and Therapeutic Suggestions for High-risk RUNX1::RUNX1T1-positive pAML patients中文题目：高危 RUNX1::RUNX1T1 阳性pAML患者的风险分层和治疗建议汇报者：Yang Xun (中国佛山)摘要号：1281P英文题目：Targeting miR-20a/RUNX1 exerts the dual functions of blocking CD8+ T cell exhaustion and anti-leukemia effect in acute myeloid leukemia中文题目：靶向 miR-20a/RUNX1在急性髓系白血病中发挥阻断CD8+ T细胞耗竭和抗白血病作用的双重作用汇报者：Yangqiu Li (中国广州)摘要号：1285P英文题目：HIF-2α expression predicts inferior survival and can broaden the poor clinical outcome of patients with Foxp3- and NF-κB+ in DLBCL中文题目：HIF-2α表达预示较差的生存期，并可加剧伴有Foxp3和NF-κB+的DLBCL患者的临床不良结局汇报者：Yaoyao Jing (中国天津)摘要号：1291eP英文题目：Pola-R-CHP Regimen as First-Line Treatment for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients中文题目：Pola-R-CHP方案作为新诊断高危弥漫大B细胞淋巴瘤 (DLBCL)患者的一线治疗汇报者：Jinping Pi (中国北京)摘要号：1294eP英文题目：Efficacy of Orelabrutinib Combined with R-CHOP(-like) Regimen in Previously Untreated Double-expression (DE) Diffuse Large B-Cell Lymphoma (DLBCL): A Single-Center Real-World Analysis中文题目：奥布替尼联合R-CHOP(类)方案治疗既往未治疗的双表达(DE)弥漫大B细胞淋巴瘤(DLBCL)的疗效：单中心真实世界分析汇报者：Min Bai (中国太原)摘要号：1298eP英文题目：PD-1/CD20 Dual-Target Therapy in Unfit Diffuse Large B-Cell Lymphoma: A Real-World Pilot Study中文题目：PD-1/CD20双靶点疗法治疗Unfit弥漫大B细胞淋巴瘤：一项真实世界先导研究汇报者：Shaozhen Chen (中国福州)摘要号：1299eP 英文题目：ADGRE2: a tumor-restricted surface antigen for immunotherapy in acute myeloid leukemia中文题目：ADGRE2：急性髓性白血病免疫治疗的肿瘤特异性表面抗原汇报者：Ruotong Chen(中国合肥)摘要号：1300eP英文题目：Synergistic Effect of Vincristine and Cytarabine via Targeting the ALDOC-JAK/STAT Axis for NRASmut Acute Myeloid Leukemia中文题目：长春新碱与阿糖胞苷通过靶向ALDOC-JAK/STAT轴对NRASmut急性髓系白血病的协同效应汇报者：Haotian Yan(中国合肥)（来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

细胞疗法免疫疗法临床2期临床1期ASH会议

2025-07-25

·ioncology

速览！目前已有30余项中国研究入选2025年ESMO大会口头发言

编者按：一年一度的欧洲肿瘤内科学会（ESMO）年会将于2025年10月17-21日在德国柏林举行。ESMO官网已更新发布入选大会发言的摘要题目。据当前统计，2025年ESMO大会上，中国有30余项研究成果入选大会口头报告发言（如有错误或遗漏，请留言更正），包括特邀论文报告（Proffered Paper session）、小型口头报告（Mini Oral session）。目前重磅的延迟突破性摘要（Late breaking abstract，LBA）尚未公布。01特邀论文报告Proffered Paper session头颈肿瘤英文题目：Perioperative camrelizumab plus chemotherapy in locally advanced squamous cell carcinoma of the head and neck (CAMORAL): A multicenter, open-label, randomized, phase II Study中文题目：卡瑞利珠单抗联合化疗围手术期治疗局部晚期头颈部鳞癌的多中心、开放、随机对照II期临床研究（CAMORAL）摘要号：1319O汇报者：何悦（上海交通大学医学院附属第九人民医院）英文题目：Concurrent Chemoradiotherapy with/without Adjuvant Capecitabine in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Controlled Phase III Trial中文题目：局部晚期鼻咽癌同步放化疗联合/不联合卡培他滨辅助治疗：一项随机、对照、III期临床试验摘要号：1321O汇报者：苗菁菁（中山大学肿瘤防治中心）血液肿瘤英文题目：CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory Large B-cell Lymphoma: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial中文题目：CD19/CD22双特异性CAR-T细胞治疗复发/难治性大B细胞淋巴瘤：一项前瞻性、单臂、单中心、II期临床试验摘要号：1240O汇报者：王亮（首都医科大学附属北京同仁医院）英文题目：Anti-PD-1-Antibody (Tislelizumab) Combined with Chidamide, Lenalidomide and Etoposide for the treatment of refractory/relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r-ENKTL): Preliminary Results from a Prospective, Multicenter, Single -Arm, Phase II Trial中文题目：抗PD-1抗体（替雷利珠单抗）联合西达本胺、来那度胺和依托泊苷治疗难治性/复发性结外NK/T细胞淋巴瘤,鼻型：一项前瞻性、多中心、单臂、II期试验的初步结果摘要号：1241O汇报者：张蕾（郑州大学第一附属医院）中枢神经系统肿瘤英文题目：Proton versus Carbon Ion Radiotherapy in Skull Base Chordoma and Chondrosarcoma: Initial Clinical Outcomes from a Phase II Randomized Trial中文：质子束与碳离子束放射治疗颅底脊索瘤和软骨肉瘤：一项 II 期随机试验的初步临床结果摘要号：656O汇报者：黄清廷（上海市质子重离子医院）英文题目：A randomized, controlled, multicenter, phase II/III clinical study to evaluate the safety and efficacy of chlorogenic acid for injection in the treatment of recurrent grade IV glioblastoma (GBM)中文题目：一项随机、对照、多中心、II/III期临床研究，评估注射用绿原酸治疗复发性IV级胶质母细胞瘤（GBM）的安全性和有效性摘要号：657O汇报者：李文斌（首都医科大学附属北京天坛医院）英文题目：Molecular diagnosis and management of leptomeningeal metastases with evolving therapeutic paradigm in advanced lung cancer中文题目：晚期肺癌轻脑膜转移的分子诊断和治疗与不断发展的治疗模式摘要号：659O汇报者：Meimei Zheng（中国广州）英文题目：Locoregional bispecific CAR-T cells targeting CD44 and CD133 show safety and efficacy in recurrent high-grade glioma in a first-in-human investigator-initiated trial中文题目：在一项由研究者发起的首次人体试验中，靶向 CD44 和 CD133 的局部区域双特异性 CAR-T 细胞在复发性高级别神经胶质瘤中显示出安全性和有效性摘要号：1511O汇报者：翟优（首都医科大学附属北京天坛医院）妇科肿瘤英文题目：Fuzuloparib (FZPL) monotherapy or in combination with apatinib (APA) as first-line (1L) maintenance therapy in advanced ovarian cancer (OC): final analysis of the FZOCUS-1 trial中文题目：FZOCUS-1研究的最终分析：氟唑帕利（FZPL）单药或联合阿帕替尼（APA）一线（1L）维持治疗晚期卵巢癌（OC）患者摘要号：1063O汇报者：李宁（中国医学科学院肿瘤医院）软组织肉瘤英文题目：ARTEMIS-002: A Phase 2 Study of HS-20093 in Patients with Relapsed or Refractory Sarcomas中文题目：II期ARTEMIS-002研究：HS-20093治疗复发性或难治性肉瘤患者摘要号：2684O汇报者：谢璐（北京大学人民医院）甲状腺癌英文题目：Efficacy and Safety of Dabrafenib Plus Trametinib (D+T) in Patients With Radioactive Iodine (RAI)-Refractory BRAF V600-Mutant Differentiated Thyroid Cancer (DTC)中文题目：达拉非尼联合曲美替尼（D+T）在放射性碘（RAI）-难治性 BRAF V600 突变型分化型甲状腺癌（DTC）患者中的疗效与安全性摘要号：2987O汇报者：高明（天津医科大学肿瘤医院）实体瘤英文题目：HRS-7058, a KRAS G12C inhibitor (G12Ci), in advanced solid tumors with KRAS G12C mutation: a phase 1, multi-center, first-in-human study中文题目：I期、多中心、首次人体研究：KRAS G12C抑制剂（G12Ci）HRS-7058治疗伴KRAS G12C突变晚期实体瘤患者摘要号：914O汇报者：黄鼎智（天津医科大学肿瘤医院）英文题目：KRAS G12D inhibitor HRS-4642 in patients with KRAS G12D-mutant advanced solid tumors: a phase 1 trial中文题目：I期研究：KRAS G12D抑制剂HRS-4642治疗伴KRAS G12D突变晚期实体瘤患者摘要号：915O汇报者：周彩存（同济大学附属东方医院）英文题目：First-in-human phase 1 study of TCR-T therapy targeting KRAS G12V in metastatic solid tumors中文题目：靶向 KRAS G12V 的 TCR-T 疗法治疗转移性实体瘤的首次人体I期研究摘要号：1514O汇报者：白雪莉（浙江大学医学院附属第一医院）02小型口头报告Mini Oral session血液肿瘤英文题目：Risk Stratification for Diffuse Large B-Cell Lymphoma by Integrating Interim 18F-FDG PET-CT Analysis and the NCCN-IPI: A Multicentre Retrospective Study中文题目：通过整合中期18F-FDG PET-CT分析和NCCN-IPI对弥漫性大B细胞淋巴瘤的风险分层：一项多中心回顾性研究摘要号：1243MO汇报者：王杰松（福建省肿瘤医院）英文题目：Combination of Mitoxantrone Hydrochloride Liposome with Chidamide in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma: Updated Results of the Phase II Study中文题目：盐酸米托蒽醌脂质体联合西达本胺治疗复发性或难治性外周T细胞淋巴瘤：II期研究的最新结果摘要号：1245MO汇报者：李志铭（中山大学肿瘤防治中心）英文题目：Single-Cell Atlas of Circulating Immunity identifies shared specific DLBCL signatures for predicting Response to R-CHOP and Anti-CD19 CAR T Therapies中文题目：循环免疫单细胞图谱确定了可预测对R-CHOP和抗CD19 CAR-T疗法的应答的共同特异性DLBCL特征摘要号：1246MO汇报者：张思聪（天津医科大学肿瘤医院）英文题目：Molecular Landscape of Distinct Follicular Lymphoma Histologic Grades: Insights from Genomic and Transcriptome Analyses中文题目：不同滤泡性淋巴瘤组织学分级的分子情况：来自基因组和转录组分析的见解摘要号：1247MO汇报者：孙聪（天津医科大学肿瘤医院）英文题目：Changes in Peripheral Blood Leukemia Stem Cells, Immune Cell Subsets, Cytokines, and Cellular Differentiation Status Before and After Venetoclax-Containing Regimen Treatment for Acute Myeloid Leukemia中文题目：急性髓系白血病含维奈克拉方案治疗前后外周血白血病干细胞、免疫细胞亚群、细胞因子和细胞分化状态的变化摘要号：1248MO汇报者：Xinyu Sun（中国合肥）肝细胞癌英文题目：Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): a multicenter, open-label, randomized phase III trial.中文题目：肝切除术对比持续阿替利珠单抗联合贝伐珠单抗用于经阿替利珠单抗联合贝伐珠单抗治疗后局部晚期肝细胞癌（HCC）的研究（TALENTop）：一项多中心、开放标签、随机 Ⅲ 期临床试验摘要号：1469MO汇报者：孙惠川（复旦大学附属中山医院）英文题目：Perioperative Camrelizumab plus Rivoceranib in Resectable Hepatocellular Carcinoma (CARES-009): A Randomized, Multicenter, Phase 3 Trial中文题目：围手术期卡瑞利珠单抗联合阿帕替尼用于可切除肝细胞癌（CARES-009）：一项随机、多中心 Ⅲ 期试验摘要号：1470MO汇报者：周俭（复旦大学附属中山医院）胰腺癌英文题目：HRS-4642 Combined with Gemcitabine and Nab-paclitaxel in KRAS-G12D Mutant Advanced Pancreatic Cancer: A Phase Ib/II Study中文题目：HRS-4642 联合吉西他滨与白蛋白结合型紫杉醇治疗 KRAS-G12D 突变的晚期胰腺癌：一项 Ib/II 期研究摘要号：2215MO汇报者：王理伟（上海交通大学医学院附属仁济医院）肺癌英文题目：Phase 2 Study of Firmonertinib in Patients with Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer (mNSCLC) with EGFR Exon 20 Insertion (Ex20ins) Mutations中文题目：伏美替尼在经治的EGFR外显子20插入（ex 20ins）突变晚期/转移性非小细胞肺癌（mNSCLC）患者中的II期研究摘要号：1848MO汇报者：Ying Cheng（中国长春）英文题目：Surgery versus radiotherapy after induction therapy with serplulimab combined with chemotherapy for unresectable stage IIIB-IIIC non-small cell lung cancer: a randomized controlled, open-label, phase 2 trial中文题目：不可切除 IIIB-IIIC 期NSCLC接受斯鲁利单抗联合化疗诱导治疗后进行手术与放疗的比较：一项随机对照、开放标签、II 期试验摘要号：1818MO汇报者：Suyu Wang（上海市肺科医院）神经内分泌癌英文题目：A Phase 2 Dose Expansion Study of ZG006, a Trispecific T Cell Engager Targeting DLL3/DLL3/CD3, as Monotherapy in Patients with Refractoy Neuroendocrine Carcinoma中文题目：ZG006（一种靶向 DLL3/DLL3/CD3 的三特异性 T 细胞衔接器）单药治疗难治性神经内分泌癌患者的II期剂量扩展研究摘要号：1707MO汇报者：赵传华（中国人民解放军总医院）英文题目：ZG005 in combination with etoposide and cisplatin for the first-line treatment of advanced neuroendocrine carcinoma中文题目：ZG005 联合依托泊苷与顺铂用于晚期神经内分泌癌的一线治疗摘要号：1708MO汇报者：Sisi Ye（中国北京）中枢神经系统肿瘤英文题目：Update on the phase II study: to explore the efficacy and safety of luvometinib (FCN-159) in recurrent or progressive pediatric low-grade glioma with MAPK pathway-activated中文题目：II期研究更新：luvometinib（FCN-159）在伴有 MAPK 通路激活的复发性或进行性低级别儿童脑胶质瘤中的疗效及安全性摘要号：661MO汇报者：李文斌（首都医科大学附属北京天坛医院）英文题目：DNA methylation-based epigenetic signatures for classification and non-invasive diagnosis of gliomas中文题目：基于 DNA 甲基化表观遗传特征的胶质瘤分类及无创诊断摘要号：665MO汇报者：王正锋（郑州大学第一附属医院）肾癌英文题目：Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): results from phase 3 part of a randomized, open-label, active-controlled phase 2/3 study (FRUSICA-2)中文题目：呋喹替尼（FRUQ）联合信迪利单抗（SIN）对比阿昔替尼（AXI）或依维莫司（EVE）单药作为二线治疗方案在局部晚期或转移性肾细胞癌（RCC）患者中的疗效：一项随机、开放标签、活性对照的II/III期研究（FRUSICA-2）的III期部分结果摘要号：2592MO汇报者：叶定伟（复旦大学附属肿瘤医院）软组织肉瘤英文题目：A phase II trial of the combination of Chidamide and Toripalimab in patients with advanced sarcoma中文题目：II期研究：西达本胺联合特瑞普利单抗治疗晚期肉瘤患者摘要号：2689MO汇报者：张星（中山大学肿瘤防治中心）甲状腺癌英文题目：Patient-Derived Organoids Predict Clinical Response and Guide Personalized Therapy in Advanced Thyroid Cancer中文题目：患者来源类器官预测晚期甲状腺癌的临床疗效并指导个性化治疗摘要号：2988MO汇报者：刘嘉烨（四川大学华西医院）实体瘤及其他英文题目：Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain: A Prospective, Randomized Phase 3 Trial中文题目：培非格司亭给药时机与培非格司亭诱导的骨痛：一项前瞻性随机III期试验摘要号：297MO汇报者：Peiyong Li（广东省人民医院）英文题目：Updated ongoing Phase I/II clinical trial results of AMT-116, a first-in-class anti-CD44v9 antibody-drug conjugate (ADC), in patients with advanced solid tumors中文题目：I/II期研究数据更新：首个first-in-class抗CD44v9抗体药物偶联物（ADC）AMT-116治疗晚期实体瘤患者摘要号：922MO汇报者：宋正波（浙江省肿瘤医院）（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

细胞疗法临床2期免疫疗法临床结果临床1期

100 项与盐酸米托蒽醌脂质体相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	盐酸米托蒽醌脂质体	L01DB07	DB01204

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
外周T细胞淋巴瘤	中国	石药集团中诺药业（石家庄）有限公司	2021-06-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
鼻咽癌	临床3期	中国	石药集团中诺药业（石家庄）有限公司合并	2023-02-15
复发性鼻咽癌	临床3期	-	石药集团中诺药业（石家庄）有限公司	2023-02-01
难治性外周T细胞淋巴瘤	临床3期	中国	石药集团中奇制药技术（石家庄）有限公司	2021-04-14
鼻咽肿瘤	临床2期	-	上海津曼特生物科技有限公司	2025-04-01
髓系肿瘤	临床2期	中国	石药集团中诺药业（石家庄）有限公司	2024-02-29
难治性急性髓细胞白血病	临床2期	中国	石药集团中诺药业（石家庄）有限公司	2024-02-29
复发性急性髓细胞白血病	临床2期	中国	石药集团中诺药业（石家庄）有限公司	2024-02-29
难治性弥漫性大 B 细胞淋巴瘤	临床2期	中国	石药集团中奇制药技术（石家庄）有限公司	2023-07-27
视神经脊髓炎	临床2期	中国	石药集团中诺药业（石家庄）有限公司	2022-11-17
复发性弥漫性大B细胞淋巴瘤	临床2期	中国	石药集团欧意药业有限公司	2022-10-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05620862 (Phase I study of mitoxantrone hydrochloride liposome, ASCO2025)	临床1期	肿瘤	7	Mitoxantrone hydrochloride liposome 16mg/m^2	鬱糧積顧獵襯壓選艱艱(齋糧廠鬱憲衊糧衊餘觸) = 壓鹽範鹹蓋選遞糧觸廠顧糧壓夢醖選鹹襯製觸 (鑰獵衊簾構繭製醖鑰糧 ) 更多	不佳	2025-05-30
				Mitoxantrone hydrochloride liposome 20mg/m^2	鬱糧積顧獵襯壓選艱艱(齋糧廠鬱憲衊糧衊餘觸) = 願齋築繭衊獵製鏇廠窪顧糧壓夢醖選鹹襯製觸 (鑰獵衊簾構繭製醖鑰糧 )
NCT04548700 (ASCO2025)	临床1期	外周T细胞淋巴瘤	38	Lipo-MIT combined with COP regimen	糧選醖觸齋膚鬱願構選(範淵獵衊簾遞衊繭鹹窪) = 簾選鏇構獵餘網繭艱醖鹽構淵衊淵積積蓋膚壓 (壓艱築窪鹹獵鏇鏇築簾, 73.3 ~ 96.8) 更多	-	2025-05-30
NCT05893329 (EHA2025) 人工标引	临床阶段不明	急性髓性白血病一线	60	Mitoxantrone hydrochloride liposome + cytarabine (MA cohort)	觸夢鬱範構繭壓襯蓋鑰(製衊築餘醖簾獵網構獵) = were comparable across cohorts, predominantly manifesting as hematologic and infectious toxicities. The common grade ≥3 non-hematologic TRAEs included infectious pneumonia (10% vs 25% vs 20%) and neutropenia-associated infections 鬱夢簾膚襯襯網膚鹽築 (鑰壓窪簾鹹蓋壓壓壓顧 )	积极	2025-05-14
				Mitoxantrone hydrochloride liposome + cytarabine + homoharringtonine (MAH cohort)
NCT05441761 (EHA2025) 人工标引	临床1/2期	外周T细胞淋巴瘤二线	19	Lipo-MIT with GDP regimen (MGDP) (all evaluable pts)	夢鏇獵鬱遞鏇衊襯膚鏇(鑰網鹹蓋積願蓋築憲窪) = 襯範網顧鹽鑰選願簾繭淵鬱網簾鏇遞艱鏇夢夢 (簾積鹽範網鹹鹽鏇顧衊, 38.4～83.7) 更多	积极	2025-05-14
				Lipo-MIT with GLipo-MITen (MGDP) (median dose of Lipo-MIT per cycle was 18.4 (range, 16.5-20.1) mg/m^2)	夢鏇獵鬱遞鏇衊襯膚鏇(鑰網鹹蓋積願蓋築憲窪) = 淵築構簾獵範簾餘襯襯淵鬱網簾鏇遞艱鏇夢夢 (簾積鹽範網鹹鹽鏇顧衊, 34.8 ~ 93.3) 更多
NCT04548700 (EHA2025) 人工标引	临床1期	外周T细胞淋巴瘤一线	38	Liposomal Mitoxantrone + cyclophosphamide, vincristine,cyclophosphamide, vincristine, and prednisone (CMOP)prednisone (CMOP)	鑰獵製鹹積選窪鏇築鑰(醖範壓廠壓淵積鬱鬱構) = neutropenia (76.3%), leukopenia (73.7%), lymphopenia (44.7%), thrombocytopenia (15.8%) and anemia (13.2%) 鑰觸窪繭衊積廠築衊齋 (鹹蓋壓鹹範窪製醖憲壓 ) 更多	积极	2025-05-14
EHA2025 人工标引	N/A	弥漫性大B细胞淋巴瘤	17	R-CDOPR-CMOP (rituximab 375 mg/m², D0; cyclophosphamide 750 mg/m², cisplatin 25 mg/m², vincristine 1.3 mg/m², D1; prednisone 100 mg, D1-5) switched to (liposomal mitoxantrone 18 mg/m²; other agents/doses identical to R-CDOP)rituximab 375 mg/m², D0; cyclophosphamide 750 mg/m², cisplatin 25 mg/m², vincristine 1.3 mg/m², D1; prednisone 100 mg, D1-5) switched to (liposomal mitoxantrone 18 mg/m²; other agents/doses identical to R-CDOP)	廠選獵艱窪網醖夢築夢(遞遞齋構顧製繭淵蓋繭) = After two R-CMOP cycles, 9 patients (52.9%) achieved complete response (CR), increasing to 12 (70.6% best response) after four cycles. 簾窪製膚願襯窪選選膚 (齋簾夢廠遞構糧鏇鏇餘 ) 更多	积极	2025-05-14
EHA2025 人工标引	N/A	急性髓性白血病一线 \| 诱导	20	liposomal mitoxantrone+venetoclax+azacitidine	製獵築獵構積淵範艱餘(簾廠願齋餘窪選膚襯襯) = 鏇簾觸憲選齋鏇獵製鹹繭齋製鹽遞鑰壓鹽鬱鏇 (獵鑰鹹糧網憲淵遞構鏇 ) 更多	积极	2025-05-14
ChiCTR2300074073 (EHA2025) 人工标引	临床2期	非霍奇金淋巴瘤一线	39	CMOP±R regimen	製鑰壓餘醖鏇蓋築廠鏇(鏇顧膚獵鑰窪襯鏇廠蓋) = 築積膚襯襯窪繭鹽鑰範蓋夢餘鏇艱衊積醖夢餘 (夢膚艱鬱觸築繭醖願廠 ) 更多	积极	2025-05-14
				R-CHOP	製鑰壓餘醖鏇蓋築廠鏇(鏇顧膚獵鑰窪襯鏇廠蓋) = 廠膚窪築廠鏇窪憲鏇膚蓋夢餘鏇艱衊積醖夢餘 (夢膚艱鬱觸築繭醖願廠 ) 更多
NCT06621212 (EHA2025) 人工标引	临床2期	复发性急性髓细胞白血病 \| 难治性急性髓细胞白血病	11	Mitoxantrone hydrochloride liposome+cytarabine+venetoclax (favorable and intermediate risk)	糧艱鹹鏇鹹鑰廠鬱築製(觸齋壓廠夢淵製鑰壓鬱) = 膚艱廠網構鹽簾獵鬱築獵齋憲艱鹹鹹鑰遞鹽積 (夢鹹願艱膚鹽衊鬱壓膚 ) 更多	积极	2025-05-14
				Mitoxantrone hydrochloride liposome+cytarabine+venetoclax (adverse risk)	糧艱鹹鏇鹹鑰廠鬱築製(觸齋壓廠夢淵製鑰壓鬱) = 鏇繭壓範餘網顧憲廠遞獵齋憲艱鹹鹹鑰遞鹽積 (夢鹹願艱膚鹽衊鬱壓膚 ) 更多
EHA2025 人工标引	临床阶段不明	急性髓性白血病 KIT Mutation \| AML1-ETO Fusion \| ASXL1 Mutation \| ... 更多	13	Mitoxantrone hydrochloride liposome + Low-dose cytarabinecytarabine (total)	艱蓋積鬱鑰憲繭築鹽窪(壓壓衊遞願蓋築餘蓋簾) = 鑰襯獵膚艱壓遞鏇廠鏇襯醖網壓廠蓋鹹願網觸 (窪鹹衊衊鹹構鏇壓蓋膚, 1 ~ 23) 更多	积极	2025-05-14
				Mitoxantrone hydrochloride liposome + Low-dose cytarabine (newly diagnosed)	廠選壓餘觸繭壓壓窪鑰(網網鏇簾顧鹹築窪廠鬱) = 憲願觸糧構鏇製鑰鏇鏇繭顧願夢鏇糧憲獵蓋艱 (鏇築鹽選鹽膚糧築襯積 ) 更多